ABSTRACT
HIV cure research is increasingly focused on anatomical tissues as sites for residual HIV replication during combined antiretroviral therapy (cART). Tissue-based HIV could contribute to low-level immune activation and viral rebound over the course of infection and could also influence the development of diseases, such as atherosclerosis, neurological disorders and cancers. cART-treated subjects have a decreased and irregular presence of HIV among tissues, which has resulted in a paucity of actual evidence concerning how or if HIV persists, replicates and evolves in various anatomical sites during therapy. In this study, we pooled 1806 HIV envelope V3 loop sequences from twenty-six tissue types (seventy-one total tissues) of six pre-cART subjects, four subjects with an unknown cART history who died with profound AIDS, and five subjects who died while on cART with an undetectable plasma viral load. A computational approach was used to assess sequences for their ability to utilize specific cellular coreceptors (R5, R5 and X4, or X4). We found that autopsied tissues obtained from virally suppressed cART+ subjects harbored both integrated and expressed viruses with similar coreceptor usage profiles to subjects with no or ineffective cART therapy (i.e., significant plasma viral load at death). The study suggests that tissue microenvironments provide a sanctuary for the continued evolution of HIV despite cART.
Subject(s)
Anti-HIV Agents/therapeutic use , Cellular Microenvironment/immunology , HIV Infections/immunology , Immune Evasion , Neoplasms/immunology , Receptors, CCR5/genetics , Receptors, CXCR4/genetics , Antiretroviral Therapy, Highly Active , Autopsy , Computational Biology , Female , Gene Expression , HIV Infections/complications , HIV Infections/drug therapy , HIV Infections/pathology , HIV-1/genetics , HIV-1/growth & development , HIV-1/immunology , Humans , Male , Neoplasms/complications , Neoplasms/drug therapy , Neoplasms/pathology , Receptors, CCR5/immunology , Receptors, CXCR4/immunology , Sequence Analysis, RNA , Viral Load/immunology , env Gene Products, Human Immunodeficiency Virus/genetics , env Gene Products, Human Immunodeficiency Virus/immunologyABSTRACT
Protease genotype, as a variable in outcome to combination therapy for human immunodeficiency virus (HIV) type 1 infection, was evaluated among protease inhibitor-naive children and adolescents who had received extensive treatment with reverse-transcriptase inhibitors. After 24 weeks of combination therapy, 35% had viral and immune success (VSIS patients), 19% had viral and immune failure (VFIF patients), and 46% had viral failure but marked improvement in CD4 T cells (VFIS patients). Disease stage was the only pretherapy clinical variable associated with outcome (P=.02). Although reverse-transcriptase genotype was unrelated to outcome, pretherapy protease genotype was related significantly to therapy response (P=.005). Odds for immune or viral failure were 17.7 to 1 and 2.5 to 1, respectively, for protease genotype as a single variable. Protease genotype combined with disease stage and CD4 cell percentage predicted correct therapy response for 81% of patients (100% of VFIF, 78% of VSIS, and 75% of VFIS patiens). Naturally occurring amino acid polymorphisms in protease provide sensitive biomarkers for treatment response among inhibitor-naive patients with advanced HIV disease.
Subject(s)
Anti-HIV Agents/therapeutic use , HIV Infections/drug therapy , HIV Protease/genetics , HIV-1/enzymology , Reverse Transcriptase Inhibitors/therapeutic use , Adolescent , Amino Acid Substitution , Child , Child, Preschool , Cohort Studies , Drug Therapy, Combination , Female , Genotype , HIV Infections/immunology , HIV Infections/virology , HIV Reverse Transcriptase/genetics , HIV-1/genetics , Humans , Infant , Male , Phylogeny , Predictive Value of Tests , Prospective Studies , Sequence Analysis, DNA , Treatment OutcomeABSTRACT
We have examined the nature of V3 sequence variability among subtype C human immunodeficiency virus type 1 (HIV-1) sequences from plasma-derived viral RNA present in infected men from Malawi. Sequence variability was assessed by direct sequence analysis of the V3 reverse transcription-PCR products, examination of virus populations by a subtype C V3-specific heteroduplex tracking assay (V3-HTA), and selected sequence analysis of molecular clones derived from the PCR products. Sequence variability in V3 among the subtype C viruses was not associated with the presence of basic amino acid substitutions. This observation is in contrast to that for subtype B HIV-1, where sequence variability is associated with such substitutions, and these substitutions are determinants of altered coreceptor usage. Evolutionary variants in subtype C V3 sequences, as defined by the V3-HTA, were not correlated with the CD4 level in the infected person, while such a correlation was found with subtype B V3 sequences. Viruses were isolated from a subset of the subjects; all isolates used CCR5 and not CXCR4 as a coreceptor, and none was able to grow in MT-2 cells, a hallmark of the syncytium-inducing phenotype that is correlated with CXCR4 usage. The overall sequence variability of the subtype C V3 region was no greater than that of the conserved regions of gp120. This limited sequence variability was also a feature of subtype B V3 sequences that do not carry the basic amino acid substitutions associated with altered coreceptor usage. Our results indicate that altered coreceptor usage is rare in subtype C HIV-1 isolates in sub-Saharan Africa and that sequence variability is not a feature of the V3 region of env in the absence of altered coreceptor usage.
Subject(s)
Genetic Variation , HIV Envelope Protein gp120/genetics , HIV Seropositivity/virology , HIV-1/genetics , Peptide Fragments/genetics , Base Sequence , DNA, Viral , Evolution, Molecular , Genetic Heterogeneity , HIV Envelope Protein gp120/metabolism , HIV-1/growth & development , HIV-1/isolation & purification , HIV-1/metabolism , Humans , Malawi , Molecular Sequence Data , Nucleic Acid Heteroduplexes , Peptide Fragments/metabolism , RNA, Viral/blood , Receptors, CCR5/metabolism , Receptors, CXCR4/metabolismABSTRACT
A large collection of natural HIV-1 integrase (IN) sequences has not previously been described. We reasoned that analysis of such sequences would address whether natural variation of HIV-1 IN contributes to the pathogenesis of AIDS and might also identify amino acid residues important for IN function. Sequences encoding HIV-1 IN were amplified from cryopreserved lymphocytes or plasma obtained at different times from 10 hemophilia patients who had been observed for up to 17 years. The region of the HIV-1 genome that encodes the 288-amino acid IN protein was sequenced from a total of 102 clones; information was obtained for 99.97% of 29,478 amino acid positions. Phylogenetic analysis indicated that patient samples were unique. Interpatient nucleic acid distances ranged from 0.8% to 4.9%, highlighting the tight conservation of this genomic region. No major differences were found between DNA and RNA or between early and late time points from the same patient. Significantly, no amino acid changes that might account for the variable rate of disease progression between patients were evident. Only one amino acid substitution involved a highly conserved residue known to be important for enzymatic activity. However, several interesting amino acid substitutions were noted, including residues within the C-terminal region of the protein for which sequence comparisons between animal retroviruses have not been very informative. These results should encourage the pursuit of anti-integrase therapies, especially inasmuch as the apparent biologic constraints on the IN sequence may deter the development of drug resistance.
Subject(s)
Acquired Immunodeficiency Syndrome/etiology , HIV Integrase/chemistry , HIV Integrase/genetics , HIV-1 , Hemophilia A/complications , Acquired Immunodeficiency Syndrome/immunology , Adult , Amino Acid Sequence , Base Sequence , CD4 Lymphocyte Count , Cohort Studies , Consensus Sequence , Conserved Sequence , DNA, Viral/chemistry , Disease Progression , HIV-1/enzymology , HIV-1/genetics , Humans , Longitudinal Studies , Male , Middle Aged , Molecular Sequence Data , Phylogeny , Polymerase Chain Reaction , RNA, Viral/chemistry , Retrospective Studies , Survivors , Viral LoadABSTRACT
HIV-1 env gene encodes a multifunctional glycoprotein that is involved in virus infectivity, interactions between the virus and the host immune system, and phenotypic characteristics of virus isolates in culture. A number of Env functions map by genetic analysis to V3, one of five hypervariable domains that compose the surface component of Env gp120. V1 and V2 hypervariable domains of Env also contribute to the phenotype of HIV-1, although relationships between V1 and V2 genotypes and biological characteristics of HIV-1 are not well defined. One limitation to genetic analysis of V1 and V2 is the extensive length variation that results from in-frame deletions or duplications of nucleotides and renders alignments difficult among V1 and V2 sequences from different populations of viruses. We developed a model to facilitate rational alignments of V1 and V2 domains independent of their length. The alignment strategy constrains gap placement in V1 and V2 so that glycan modification motifs and potential alpha helices are intact. The alignment model accommodates the spectrum of HIV-1 subtypes, as well as HIV-2 and SIV V1 and V2 sequences. The model will facilitate genetic analysis and interpretation of amino acid changes in the hypervariable domains. For example, charged and uncharged amino acids are conserved in defined positions in each of the V1 and V2 hypervariable domains from a subset of HIV-1 subtype B isolates. Biochemical characteristics of amino acids in V1 and V2 appear unrelated to cytotropic or syncytium-inducing phenotypes of the viruses.
Subject(s)
Genes, env , HIV Envelope Protein gp120/genetics , HIV-1/genetics , Models, Genetic , Sequence Alignment , Simian Immunodeficiency Virus/genetics , Amino Acid Sequence , Animals , Haplorhini , Humans , Molecular Sequence DataABSTRACT
Reduced sensitivity of human immunodeficiency virus type 1 (HIV-1) to protease inhibitors is associated with multiple amino acid substitutions in the virus-encoded protease. The combination of changes that contribute to drug resistance is dependent in part upon the amino acid residues comprising protease alleles prior to drug therapy. We analyzed within peripheral blood mononuclear cells from HIV-1-infected mothers and their children viral gag/pol regions, which included p7, transframe p6/p6*, and protease coding sequences, as well as six protease cleavage sites. Sixty protease alleles from 12 individuals differed by at least 3 to as many as 10 amino acids from proteases encoded by molecular clones of HIV-1, indicating that there is no prototype or consensus wild-type HIV-1 protease sequence. Protease variants with a proline at position 63, a substitution associated with resistance to protease inhibitors, appeared in the absence of antiprotease therapy in 7 patients and were transmitted by 2 mothers to their infants. Gag p7 p6 regions were significantly more variable than protease. The p6/p6* region contained length variants and amino acid repeats in both reading frames. Five protease cleavage sites (B, D', D, E, and F) contained highly conserved amino acid sequences in individuals infected by epidemiologically distinct viruses. In contrast, C cleavage sites, localized between Gag p2 and Gag p7, displayed considerable amino acid variability, were unique among groups of infected individuals, and appeared to be related to particular protease alleles. Genetic variability in vivo in protease, in cleavage sites, and in proteins upstream of protease provides the potential to modulate enzyme activity and susceptibility to protease inhibitors.
Subject(s)
Capsid Proteins , Capsid/genetics , Gene Products, gag/genetics , Gene Products, pol/genetics , Genetic Variation , HIV Infections/virology , HIV Protease/genetics , HIV-1/genetics , Viral Proteins , Alleles , Amino Acid Sequence , Antiviral Agents/therapeutic use , Base Sequence , Binding Sites , Capsid/metabolism , Child , Cross-Sectional Studies , DNA Primers , Gene Products, gag/metabolism , Gene Products, pol/metabolism , HIV Infections/drug therapy , HIV Protease/metabolism , HIV Protease Inhibitors/therapeutic use , HIV-1/classification , HIV-1/enzymology , Humans , Molecular Sequence Data , Phylogeny , Protein Precursors/genetics , gag Gene Products, Human Immunodeficiency Virus , pol Gene Products, Human Immunodeficiency VirusABSTRACT
The extent of nucleotide variation within the HIV-1 env hypervariable domains serves as a marker of virus genotypes within infected individuals and as a means to track transmission of the virus between individuals. We analyzed env V1 and V2 sequences in longitudinal samples from two HIV-1-infected mothers, each with three children infected by maternal transmission of the virus. Sequences in samples that were obtained from two infants at 2 d and 4 wk after birth displayed more variation in V1 and V2 than maternal samples obtained at the same times. Multiple HIV-1 genotypes were identified in each mother. In each family, multiple maternal HIV-1 genotypes were transmitted to the infants. Specific amino acid residues in the hypervariable domains were conserved within sequences from each family producing a family-specific amino acid signature pattern in V1 and V2. Viruses that were highly related to maternal viruses in signature pattern persisted for as long as 4 yr in the older children. Results support a model of transmission involving multiple HIV-1 genotypes with development of genetic variation from differential outgrowth and accumulation of genetic changes within each individual.
Subject(s)
Acquired Immunodeficiency Syndrome/transmission , Gene Products, env/genetics , Genetic Variation , HIV-1/genetics , HIV-1/isolation & purification , Phylogeny , Pregnancy Complications, Infectious/microbiology , Acquired Immunodeficiency Syndrome/microbiology , Amino Acid Sequence , Child, Preschool , Female , Genes, env , Genotype , Humans , Infant , Infant, Newborn , Longitudinal Studies , Molecular Sequence Data , Pregnancy , Sequence Homology, Amino AcidABSTRACT
Multiple targets for immune recognition and cellular tropism are localized to the V1 and V2 hypervariable regions in the amino portion of human immunodeficiency virus type 1 (HIV-1) gp120env. We have assessed genetic diversity in env V1 and V2 hypervariable domains in vivo within epidemiologically related strains of HIV-1. Our strategy was to analyze longitudinal samples from two seropositive mothers and multiple children infected by perinatal transmission. Although the V1 and V2 domains are closely linked in the HIV-1 genome, nucleotide sequences in V1 and in V2 evolved independently in maternal-infant viruses in vivo. A high proportion of the nucleotide substitutions would introduce amino acid diversity in V1 and in V2. A significant excess of nonsynonymous over synonymous substitutions was identified in HIV-1 env V1 and V2 peptides in the mothers and in two older children but was not generally apparent in HIV-1 sequences in infants. An excess of nonsynonymous over synonymous substitutions indicated that there is positive selection for independent genetic variation in the V1 and V2 domains in vivo. It is likely that there are host responses to complex determinants in the V1 or V2 hypervariable domain of HIV-1 gp120.